U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H8N2O2
Molecular Weight 176.172
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PEMOLINE

SMILES

NC1=NC(=O)C(O1)C2=CC=CC=C2

InChI

InChIKey=NRNCYVBFPDDJNE-UHFFFAOYSA-N
InChI=1S/C9H8N2O2/c10-9-11-8(12)7(13-9)6-4-2-1-3-5-6/h1-5,7H,(H2,10,11,12)

HIDE SMILES / InChI
Molecular Formula C9H8N2O2
Molecular Weight 176.172
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Pemoline is a central nervous system stimulant. Pemoline is structurally dissimilar to the amphetamines and methylphenidate. Pemoline is generally considered dopaminergic, but its precise method of action hasn't yet been definitively determined. The interaction of pemoline with other drugs has not been studied in humans. The following are adverse reactions in decreasing order of severity within each category associated with pemoline: hepatic dysfunction, aplastic anemia, convulsive seizures, hallucinations, insomnia, anorexia and weight loss.

CNS Activity

CNS Active
3,913

Originator

Traube, W.
1

Approval Year

1975
63

Targets

Primary TargetPharmacologyConditionPotency
Dopaminergic synapse
2
Agonist
2,678

Conditions

ConditionModalityTargetsHighest PhaseProduct
Attention deficit hyperactivity disorder
68
 Primary
Approved
8,429
CYLERT

Cmax

ValueDoseCo-administeredAnalytePopulation
2.76 μg/mL
2 mg/kg single, oral
 PEMOLINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
46.2 μg × h/mL
2 mg/kg single, oral
 PEMOLINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
7.28 h
2 mg/kg single, oral
 PEMOLINE plasma
Homo sapiens

Doses

AEs

PubMed

Patents

CA2271197A1
1
EP0948490A1
1
US5677463
1
WO1998022450 A1
1

Sample Use Guides

In Vivo Use Guide
Starting dose is 37.5 mg/day Daily dose should be gradually increased by 18.75 mg at one week intervals The effective daily dose for most patients will range from 56.25 to 75 mg Maximum recommended daily dose is 112.5 mg.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
7GAQ2332NK
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966